Post/November 10, 2026Silevertinib heads for a Phase 3 trial built around lung cancer that has spread to the brainBlack Diamond plans a silevertinib Phase 3 trial in 2027 for EGFR lung cancer with brain metastases, after an FDA meeting and new Phase 2 data.HNHealthcare News·November 10, 2026
